These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10233562)

  • 21. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
    Freeman R; Hill S; Millard R; Slack M; Sutherst J;
    Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
    Abrams P; Malone-Lee J; Jacquetin B; Wyndaele JJ; Tammela T; Jonas U; Wein A
    Drugs Aging; 2001; 18(7):551-60. PubMed ID: 11482747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hallucinations with tolterodine.
    Williams SG; Staudenmeier J
    Psychiatr Serv; 2004 Nov; 55(11):1318-9. PubMed ID: 15534031
    [No Abstract]   [Full Text] [Related]  

  • 25. Medical treatment of overactive bladder.
    Rackley R; Wein A; Nelson D
    Mayo Clin Proc; 2001 Nov; 76(11):1179-80. PubMed ID: 11702910
    [No Abstract]   [Full Text] [Related]  

  • 26. Is extended-release oxybutynin (Ditropan XL) or tolterodine (Detrol) more effective in the treatment of an overactive bladder?
    Hartnett NM; Saver BG
    J Fam Pract; 2001 Jul; 50(7):571. PubMed ID: 11485700
    [No Abstract]   [Full Text] [Related]  

  • 27. Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
    Staskin DR; Dmochowski RR; Wein AJ
    Curr Urol Rep; 2005 Nov; 6(6):403-4. PubMed ID: 16238911
    [No Abstract]   [Full Text] [Related]  

  • 28. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.
    Abrams P
    Expert Opin Pharmacother; 2001 Oct; 2(10):1685-701. PubMed ID: 11825311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder.
    Raes A; Hoebeke P; Segaert I; Van Laecke E; Dehoorne J; Vande Walle J
    Eur Urol; 2004 Feb; 45(2):240-4. PubMed ID: 14734013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model.
    Kobelt G; Jönsson L; Mattiasson A
    Neurourol Urodyn; 1998; 17(6):599-611. PubMed ID: 9829424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic treatment for detrusor overactivity.
    Lai HH; Boone TB; Appell RA
    Curr Urol Rep; 2002 Oct; 3(5):365-72. PubMed ID: 12354344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed incontinence.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2055-7. PubMed ID: 15879826
    [No Abstract]   [Full Text] [Related]  

  • 33. Tolterodine: an overview.
    Wefer J; Truss MC; Jonas U
    World J Urol; 2001 Nov; 19(5):312-8. PubMed ID: 11760779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
    Malone-Lee JG; Walsh JB; Maugourd MF
    J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
    Tubaro A; De Nunzio C
    BJU Int; 2013 Aug; 112(3):281-2. PubMed ID: 23826839
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of the overactive bladder with detrusitol].
    Golomb J
    Harefuah; 2000 Dec; 139(11-12):467-70. PubMed ID: 11341197
    [No Abstract]   [Full Text] [Related]  

  • 38. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.